Course contents

Challenging Cases in Cancer: TP53 Mutant Myeloid Neoplasms

  • In support of improving patient care, this activity has been planned and implemented by Fast4ward Learning. Pinnacle Conference, LLC is jointly accredited by the Accreditation Council  for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education  for the healthcare team.
  • Audience: This activity is designed for hematology/oncology physicians, advanced practice providers, and other clinicians involved in the care of patients with myelodysplastic syndromes and acute myeloid leukemia. 
  • This activity offers 1 CE credit for: Physicians (AMA PRA Category 1™), Nurses: ANCC NCPD, Pharmacists: ACPE CPE, Physician Assistants: APA Category 1, Psychologists APA CME, Social Workers: ASWB-ACE, Other: All other attendees will receive an AMA PRA Category 1™ participation certificate.
  • Post-program test 
    Post-program survey
    Write your awesome label here.
    Write your awesome label here.
    Moderated by:

    Dr. Rami Komrokji

    Rami Komrokji, MD, is Professor of Medicine and Oncologic Sciences at the University of South Florida College of Medicine and Vice Chair of the Malignant Hematology Department at Moffitt Cancer Center in Tampa, Florida. At Moffitt, he also serves as Senior Head of the Leukemia and MDS Section and Senior Member of the Malignant Hematology and Experimental Therapeutics Program. Dr. Komrokji earned his medical degree from the Jordan University School of Medicine, followed by an Internal Medicine residency at Case Western Reserve University. He completed his fellowship in Hematology/Oncology and Hematopoietic Stem Cell Transplantation at the University of Rochester, Strong Memorial Hospital. His clinical and research expertise focuses on myeloid neoplasms, with an emphasis on Phase I/II clinical trials and outcomes research. Dr. Komrokji has authored or coauthored more than 350 peer-reviewed publications, 20 book chapters, and over 1,000 scientific abstracts in the field of hematologic malignancies. He previously served on the NCCN Myelodysplastic Syndromes Panel and is a peer reviewer for leading journals, including Blood, Journal of Clinical Oncology, and Leukemia.